Patient Education
Share your love
ASCRS Congress 2024 Set to Take Place in April 5-8
From April 5 to 8, 2024, the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting is set to take place in Boston, USA, at the Boston Convention & Exhibition Center. This annual meeting is a pivotal event for…
ABVC BioPharma and ForSeeCon Ink Global Agreement
ABVC BioPharma, Inc. has entered into a significant global licensing agreement with ForSeeCon Eye Corporation (FEYE), marking a pivotal moment for the clinical-stage biopharmaceutical company known for its developments in ophthalmology, CNS, and oncology The agreement focuses on ABVC’s ophthalmology…
Opus Genetics’ LCA5 Therapy Enters Phase 1/2 Trial
Opus Genetics recently completed the first stage of its innovative clinical trial, focusing on a new treatment for patients suffering from Leber congenital amaurosis (LCA) due to biallelic mutations in the LCA5 gene. The trial, which is in the phase…
Iveric Bio Secures Key J-code for GA Therapy, Izervay
In a significant development for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), Iveric Bio, a subsidiary of Astellas Pharma, has been granted a unique, permanent J-code by the Centers for Medicare & Medicaid Services (CMS) for…
Rayner Reduces Carbon with Green Packaging
Rayner announced a significant update to its packaging, marking a pivotal step towards achieving its environmental objectives while also enhancing the customer experience. The company has introduced several innovative changes designed to reduce its carbon footprint and improve the practicality…
Algae-Derived Hydrogel Offers Hope for Retinal Detachment
A recent study has introduced an innovative approach to treating retinal detachment through an artificial vitreous body made from alginate, a natural carbohydrate extracted from algae. This research represents a collaboration among experts from Pohang University of Science and Technology…
BlueRock and Foundation Fighting Blindness Partner for IRD Study
BlueRock Therapeutics LP, a clinical-stage cell therapy company and a subsidiary of Bayer, in partnership with Foundation Fighting Blindness, has announced their collaboration to introduce a new cohort to the Foundation’s ‘Uni-Rare natural history study’. This initiative focuses on individuals…
Nanodropper Adaptor Proven Effective in IOP Management
In a pivotal development in the field of ophthalmology, Nanodropper Inc announced that the results from a clinical trial evaluating the Nanodropper® Adaptor have been published in the esteemed journal, Ophthalmology. The study’s findings indicate that there was no clinically…
The Intersection of Eye Imaging and Artificial Intelligence
In a review published in MedComm – Future Medicine, a research team led by Gao Yuanxu from Macau University of Science and Technology, with Miao Hanpei of Southern Medical University as the first author, sheds light on the promising intersection…
England’s Oversight in Care for the Visually Impaired
A Freedom of Information (FOI) request has brought to light a concerning issue: thousands of blind and partially sighted individuals in England are being denied essential rehabilitation services, which are crucial for adapting to life after sight loss. This revelation…